New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:14 EDTTKC, NSH, INDB, TESO, TEVA, NS, BANC, PPC, SIGI, LOWOn The Fly: Analyst Upgrade Summary
Banc of California (BANC) upgraded to Buy from Neutral at Sterne Agee... Independent Bank (INDB) upgraded to Outperform from Market Perform at Keefe Bruyette... Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer... NuStar Energy (NS) upgraded to Buy from Neutral at Goldman... NuStar GP Holdings (NSH) upgraded to Neutral from Sell at Goldman... Selective Insurance (SIGI) upgraded to Outperform from Market Perform at Keefe Bruyette... Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan... Turkcell (TKC) upgraded to Buy from Neutral at UBS... Pilgrim's Pride (PPC) upgraded to Overweight from Equal Weight at Stephens... Tesco (TESO) upgraded to Overweight from Equalweight at Capital One.
News For BANC;INDB;LOW;NS;NSH;SIGI;TEVA;TKC;PPC;TESO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
06:03 EDTLOWLowe's reports Q1 SSS up 5.3%
06:02 EDTLOWLowe's reports Q1 EPS 70c, consensus 74c
Subscribe for More Information
May 19, 2015
15:00 EDTLOWNotable companies reporting before tomorrow's open
Subscribe for More Information
14:54 EDTNSNuStar Energy, CHS pursue alliance to expand pipeline, terminal infrastructure
Subscribe for More Information
14:48 EDTLOWLowe's June 72.5 straddle priced for 5.5% movement into Q1
Subscribe for More Information
14:34 EDTLOWLowe's volatility elevated into Q1 and outlook
Subscribe for More Information
13:04 EDTLOWEarnings Watch: Lowe's sees FY15 EPS $3.29, strongest comps of year in Q1
Lowe's Companies (LOW), a home improvement retailer, is scheduled to report on its first quarter before the market open on Wednesday, May 20, with a conference call scheduled for 9:00 am ET. EXPECTATIONS: Analysts are looking for earnings per share of 74c on revenue of $14.27B, according to First Call. The consensus range for EPS is 69c-80c on revenue of $13.97B-$14.52B. LAST QUARTER: Lowe's reported fourth quarter EPS of 46c on revenue of $12.54B, beating analyst's estimates of 44c and $12.31B, respectively. The company also reported Q4 same-store sales rose 7.3%, with U.S. comparable sales up 7.4%. The company forecast fiscal year 2015 EPS $3.29 against estimates at that time for $3.28 and said it expects revenue up 4.5%-5% in the fiscal year compared to last. Lowe's also forecast FY15 SSS up 4%-4.5% and said it expects to report the highest comp for FY15 in Q1. On its earnings conference call, the company said it expects higher comps in the first half of 2015 than the second half. The company said it expects jobs, incomes and household financial conditions to improve in 2015. NEWS: During the quarter, Lowe's announced a new $5B share repurchase program, which has no expiration date and adds to the previous program's balance, which was $2.4B at January 30. Seeking Alpha contributor Xuhua Zhou, described as a hedge fund analyst, recently wrote in a blog post that "research confirms Lowe's is guilty of formaldehyde noncompliance in sourcing laminate flooring from China." The Consumer Products Safety Commission and Environmental Protection Agency should include Lowe's products in their safety testing of Lumber Liquidators' (LL) wood, the writer believes. A Lowe's spokesperson told Bloomberg that the Tescun flooring is being removed from stores. Lowe's Canada recently reached an agreement to acquire the leases of 13 former Target (TGT) Canada Locations and will buy Target's Milton, Ontario distribution center for approximately C$151M. STREET RESEARCH: On the day after its last earnings report, UBS raised its price target on Lowe's to $83 from $75, citing the company's big ticket comp growth, the improving economy and pent up demand from consumers putting projects on hold since the downturn. Argus also raised its price target, to $82 from $70, and said its confidence in the company's ability to generate profitable growth has increased. In March, Oppenheimer raised its price target on Lowe's to $85 from $77 and said the stock has a number of positive catalysts, including solid U.S. consumer spending trends, significant slack in the U.S, housing recovery, improving market sentiment and investors' interest in domestic plays as the dollar strengthens. BofA/Merrill said the home improvement space is one of the more attractive areas within retail and recommends buying Lowe's. The firm remains positive on the company's earnings growth and lack of negative catalysts. PRICE ACTION: Over the last three months, Lowe's shares are up nearly 1%. In early afternoon trading ahead of Wednesday's report, Lowe's is fractionally lower at $72.77.
07:20 EDTINDBSunTrust to hold a conference
Financial Services Conference is being held in New York on May 19-20.
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 15, 2015
17:08 EDTTEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
16:34 EDTNSNuStar Energy files $500M of common units representing limited partner interests
Subscribe for More Information
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
09:03 EDTLOWBofA/Merrill says to buy Home Depot, Lowe's and Whirlpool
Subscribe for More Information
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
May 14, 2015
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
May 13, 2015
11:12 EDTNSHEnergy MLPs weak despite Williams deal for Williams Partners
Subscribe for More Information
09:44 EDTNSHMLPs that could trade up on Williams, Williams Partners news, says Credit Suisse
Credit Suisse said Plains GP Holdings (PAGP), Targa Resources (TRGP), NuStar (NSH), Western Gas Equity (WGP) could trade up on the Williams (WMB)/Williams Partners (WPZ) merger news.
08:02 EDTTEVAANI Pharmaceuticals acquires rights to testosterone gel 1%
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use